Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?D. Deniffel, E. Salinas, M. Ientilucci, A. J. Evans, N. Fleshner, S. Ghai, R. Hamilton, A. Roberts, A. Toi, T. van der Kwast, A. Zlotta, A. Finelli, M. A. Haider and N. Perlis J Urol 2020; doi: 10.1097/JU.0000000000001157
- PMID: 32698715
- DOI: 10.1097/JU.0000000000001295
Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?D. Deniffel, E. Salinas, M. Ientilucci, A. J. Evans, N. Fleshner, S. Ghai, R. Hamilton, A. Roberts, A. Toi, T. van der Kwast, A. Zlotta, A. Finelli, M. A. Haider and N. Perlis J Urol 2020; doi: 10.1097/JU.0000000000001157
Comment in
-
Reply by Authors.J Urol. 2020 Nov;204(5):1066-1067. doi: 10.1097/JU.0000000000001296. Epub 2020 Jul 23. J Urol. 2020. PMID: 32698718 No abstract available.
Comment on
-
Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?J Urol. 2020 Dec;204(6):1187-1194. doi: 10.1097/JU.0000000000001157. Epub 2020 Jun 4. J Urol. 2020. PMID: 32496160
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical